SCHEDULE: RTW Investments Reports 0% Stake in RAPT Therapeutics

RTW Investments, LP and Roderick Wong have filed a Schedule 13G, reporting no beneficial ownership of RAPT Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• RTW Investments, LP, an investment adviser to certain funds (the "RTW Funds"), and Roderick Wong, M.D., Managing Partner and Chief Investment Officer of RTW Investments, have filed an amendment to their Schedule 13G filing.
• This filing pertains to RAPT Therapeutics, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively hold 0 shares of RAPT Therapeutics, Inc. common stock.
• This represents 0.0% of the class of securities.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it indicates a complete lack of investment from a known investment firm, which could imply a lack of confidence or a strategic exit.

Positives

• The filing confirms that RTW Investments and Roderick Wong do not hold any shares, indicating no current activist or controlling stake in RAPT Therapeutics.
• The reporting persons certify that their holdings (or lack thereof) are in the ordinary course of business and not intended to influence control of the company.

Negatives

• The filing indicates a complete divestment or lack of investment by RTW Investments and Roderick Wong in RAPT Therapeutics as of the reporting date.

Risks

• While not explicitly stated as a risk in this filing, a complete lack of beneficial ownership by a known investment firm could signal a lack of confidence in the company's future prospects or a strategic shift away from the company's sector.

Future Outlook

No forward-looking statements or guidance are provided in this Schedule 13G filing.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically used by passive investors who own more than 5% of a company's stock. The absence of any beneficial ownership reported by RTW Investments, an investment adviser, suggests a complete lack of current investment in RAPT Therapeutics by this entity.

Stakeholder Impact

• Shareholders may interpret the lack of investment by RTW Investments as a signal of potential future underperformance or a lack of institutional interest.

Next Steps

• Monitor future filings from RTW Investments and Roderick Wong for any potential re-entry into RAPT Therapeutics' stock.
• Observe RAPT Therapeutics' performance and strategic announcements to understand potential reasons for RTW's lack of investment.

Key Dates

Keywords

RAPT Therapeutics, Schedule 13G, RTW Investments, Roderick Wong, SEC Filing, Beneficial Ownership, Investment Adviser, Common Stock